Natalizumab shows promise for teens with multiple sclerosis

February 22, 2013
Natalizumab shows promise for teens with multiple sclerosis
Natalizumab may be safe in pediatric multiple sclerosis patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.

(HealthDay)—Natalizumab may be safe in pediatric multiple sclerosis (MS) patients with highly active disease, according to a small study published online Feb. 18 in JAMA Neurology.

Barbara Kornek, M.D., from the Medical University of Vienna, and colleagues retrospectively reviewed data on 20 pediatric patients with MS who started treatment with natalizumab (300 mg every four weeks) prior to 18 years of age (mean age at initiation, 16.7 years). These patients underwent MRI as clinically indicated, despite the fact that 19 of the patients were undergoing first-line disease-modifying therapy.

The researchers found that treatment with natalizumab was associated with significant reductions in mean annualized (3.7 without treatment versus 0.4 with treatment), median Expanded Disability Status Scale scores (two without treatment versus one with treatment), and mean number of new T2/fluid-attenuated inversion recovery lesions per year (7.8 without treatment versus 0.5 with treatment). Two patients had to stop therapy due to development of high-titer neutralizing antibodies against natalizumab. Other included headaches, asthenia, infections, and hypersensitivity. Eight patients had abnormal laboratory results, with John Cunningham virus found in five of 13 patients. Relapse activity occurred in six of eight patients within six months following discontinuation of natalizumab therapy.

"Our data indicate that natalizumab may be safe and effective against MS in with breakthrough disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Biogen Idec, the manufacturer of .

Explore further: Remitting multiple sclerosis: Natalizumab reduces relapses and disability

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

In treated MS, early disease activity predicts poor outcome

September 27, 2012

(HealthDay)—After 15 years of follow-up, patients with relapsing-remitting multiple sclerosis (RRMS) who display disease activity despite treatment with interferon (IFN)β-1a tend to have unfavorable long-term outcomes, ...

Recommended for you

New insights on how cocaine changes the brain

November 25, 2015

The burst of energy and hyperactivity that comes with a cocaine high is a rather accurate reflection of what's going on in the brain of its users, finds a study published November 25 in Cell Reports. Through experiments conducted ...

Can physical exercise enhance long-term memory?

November 25, 2015

Exercise can enhance the development of new brain cells in the adult brain, a process called adult neurogenesis. These newborn brain cells play an important role in learning and memory. A new study has determined that mice ...

Brain connections predict how well you can pay attention

November 24, 2015

During a 1959 television appearance, Jack Kerouac was asked how long it took him to write his novel On The Road. His response – three weeks – amazed the interviewer and ignited an enduring myth that the book was composed ...

Umbilical cells help eye's neurons connect

November 24, 2015

Cells isolated from human umbilical cord tissue have been shown to produce molecules that help retinal neurons from the eyes of rats grow, connect and survive, according to Duke University researchers working with Janssen ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.